Association of low-income subsidy, medicaid dual eligibility, and disability status with high-risk medication use among Medicare Part D beneficiaries
Name:
RSAP_Text_v2_30Apr2021trackedF ...
Size:
365.7Kb
Format:
PDF
Description:
Final Accepted Manuscript
Author
Chinthammit, ChanaddaBhattacharjee, Sandipan
Lo-Ciganic, Wei-Hsuan
Axon, David R.
Slack, Marion
Bentley, John P.
Warholak, Terri L.
Affiliation
Department of Pharmaceutical Sciences, College of Pharmacy, University of ArizonaDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Arizona
Issue Date
2021-05Keywords
DisabilityHigh-risk medication
Low-income subsidy
Medicaid dual eligibility
Medicare
Quality measures
Metadata
Show full item recordPublisher
Elsevier BVCitation
Chinthammit, C., Bhattacharjee, S., Lo-Ciganic, W. H., Axon, D. R., Slack, M., Bentley, J. P., & Warholak, T. L. (2021). Association of Low-Income Subsidy, Medicaid Dual Eligibility, and Disability Status with High-Risk Medication Use Among Medicare Part D Beneficiaries. Research in Social and Administrative Pharmacy.Rights
© 2021 Elsevier Inc. All rights reserved.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Low-income subsidy/dual eligibility (LIS/DE) status and disability status may be associated with high-risk medication (HRM) use but are not usually accounted for in medication-use quality measures. Objective: To examine the association of: 1) LIS/DE status and HRM use; and 2) disability status and HRM use, while controlling for both health plan level effects and patient characteristics for Medicare beneficiaries enrolled in Medicare Advantage Prescription Drug Plans (MA-PD) and stand-alone Prescription Drug Plans (PDP). Methods: This retrospective cross-sectional study used 2013 Medicare data to determine if LIS/DE status and disability status were independently associated with HRM use (using the Pharmacy Quality Alliance HRM measure) in MA-PDs and PDPs. Multivariable generalized linear mixed models assessed the association of LIS/DE and HRM use, and disability and HRM use, after adjusting for health plan effect and patient-level confounders for MA-PD and PDP beneficiaries. Results: Of 520,019 MA-PD beneficiaries, 88,693 (17.1%) were LIS/DE and 48,997 (9.4%) were disabled. Of 881,264 PDP beneficiaries, 213,096 (24.2%) were LIS/DE, and 83,593 (9.5%) were disabled. LIS/DE beneficiaries had a higher percent of HRM users compared to non-LIS/DE MA-PD (13.3% vs. 9.7%, p < 0.001) and PDP (17.1% vs. 13.2%, p < 0.001) beneficiaries. Disabled beneficiaries had a higher percent of HRM users compared to non-disabled MA-PD (17.0% vs. 9.6%, p < 0.001) and PDP (22.9% vs. 13.2%, p < 0.001) beneficiaries. Multivariable analyses showed LIS/DE (adjusted odds ratio [AOR] = 1.07; 95% CI = 1.04, 1.10) and disability (AOR = 1.38; 95% CI = 1.34, 1.42) were associated with HRM use among MA-PD and PDP beneficiaries (LIS/DE AOR = 1.14; 95% CI = 1.12, 1.16; disability AOR = 1.37; 95% CI = 1.34, 1.40). Conclusions: The association of LIS/DE and disability with higher HRM use in both MA-PD and PDP beneficiaries, when controlling for health plan effects and patient characteristics, suggests these factors should be considered when comparing health plan performance on HRM measures. © 2021 Elsevier Inc.Note
12 month embargo; available online 11 May 2021ISSN
1551-7411Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1016/j.sapharm.2021.05.005